Oral etoposide for kaposi’s mediterranean sarcoma

Lucia Brambilla, V. Boneschia, S. Fossati, E. Melotti, M. Clericib

Research output: Contribution to journalArticle

Abstract

22 patients affected by locally aggressive or generalized form of Kaposi’s Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2%) and gastrointestinal (64.7%) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6%) and pretreated (70%) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study withvinblastine are discussed.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalDermatology
Volume177
Issue number6
DOIs
Publication statusPublished - 1988

Fingerprint

Kaposi's Sarcoma
Etoposide
Pharmaceutical Preparations
Maintenance
Therapeutics

Keywords

  • Etoposide
  • Kaposi’s Mediterranean sarcoma
  • Systemic oral chemotherapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Brambilla, L., Boneschia, V., Fossati, S., Melotti, E., & Clericib, M. (1988). Oral etoposide for kaposi’s mediterranean sarcoma. Dermatology, 177(6), 365-369. https://doi.org/10.1159/000248608

Oral etoposide for kaposi’s mediterranean sarcoma. / Brambilla, Lucia; Boneschia, V.; Fossati, S.; Melotti, E.; Clericib, M.

In: Dermatology, Vol. 177, No. 6, 1988, p. 365-369.

Research output: Contribution to journalArticle

Brambilla, L, Boneschia, V, Fossati, S, Melotti, E & Clericib, M 1988, 'Oral etoposide for kaposi’s mediterranean sarcoma', Dermatology, vol. 177, no. 6, pp. 365-369. https://doi.org/10.1159/000248608
Brambilla L, Boneschia V, Fossati S, Melotti E, Clericib M. Oral etoposide for kaposi’s mediterranean sarcoma. Dermatology. 1988;177(6):365-369. https://doi.org/10.1159/000248608
Brambilla, Lucia ; Boneschia, V. ; Fossati, S. ; Melotti, E. ; Clericib, M. / Oral etoposide for kaposi’s mediterranean sarcoma. In: Dermatology. 1988 ; Vol. 177, No. 6. pp. 365-369.
@article{38bcd23032bc4e7ea78a70c53f2cf121,
title = "Oral etoposide for kaposi’s mediterranean sarcoma",
abstract = "22 patients affected by locally aggressive or generalized form of Kaposi’s Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2{\%}) and gastrointestinal (64.7{\%}) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6{\%}) and pretreated (70{\%}) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study withvinblastine are discussed.",
keywords = "Etoposide, Kaposi’s Mediterranean sarcoma, Systemic oral chemotherapy",
author = "Lucia Brambilla and V. Boneschia and S. Fossati and E. Melotti and M. Clericib",
year = "1988",
doi = "10.1159/000248608",
language = "English",
volume = "177",
pages = "365--369",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Oral etoposide for kaposi’s mediterranean sarcoma

AU - Brambilla, Lucia

AU - Boneschia, V.

AU - Fossati, S.

AU - Melotti, E.

AU - Clericib, M.

PY - 1988

Y1 - 1988

N2 - 22 patients affected by locally aggressive or generalized form of Kaposi’s Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2%) and gastrointestinal (64.7%) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6%) and pretreated (70%) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study withvinblastine are discussed.

AB - 22 patients affected by locally aggressive or generalized form of Kaposi’s Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2%) and gastrointestinal (64.7%) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6%) and pretreated (70%) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study withvinblastine are discussed.

KW - Etoposide

KW - Kaposi’s Mediterranean sarcoma

KW - Systemic oral chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0024214675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024214675&partnerID=8YFLogxK

U2 - 10.1159/000248608

DO - 10.1159/000248608

M3 - Article

C2 - 2466707

AN - SCOPUS:0024214675

VL - 177

SP - 365

EP - 369

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 6

ER -